+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
ID05810402

Investigating Liquid Biopsy to Predict Immunotherapy Success in Advanced Liver Cancer Hepatocellular Carcinoma

Led by University Hospital, Montpellier · Updated on 2025-07-10

60

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating advanced hepatocellular carcinoma HCC, a common and serious form of liver cancer, focusing on patients at stages B and C. This study aims to identify predictive biomarkers using a multi-omic liquid biopsy approach, which analyzes circulating tumor cells CTCs and immune profiles. It also examines whether there is a link between PD-L1 expression in tissue biopsies and in circulating tumor cells from blood samples. The goal is to better understand immunotherapy effectiveness in these patients. Participants will provide 30mL blood samples at several time points, including before treatment starts and during routine care follow-ups. Blood is collected using specialized tubes for various analyses such as CTC detection, immune cell studies, and biobanking. The study uses a non-invasive liquid biopsy method to track tumor progression and immune response. There is no placebo or comparison treatment as this is an observational assessment alongside standard care. During the study, participants will have blood drawn during regular visits, either in consultation or outpatient settings. Researchers will measure the percentage and number of PD-L1 positive CTCs at baseline, perform immune profiling over a 24-month follow-up, and analyze tumor control and survival outcomes. The study also involves tissue PD-L1 expression analysis at inclusion. Participants may be followed for up to two years to assess progression-free and overall survival while continuing their usual care.

CONDITIONS

Brief Title

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

Research Team

T

Thomas Bardol, M.D.

C

Catherine Guillemare

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here